M-x is a member of the M-2 gene family, which is expressed at high levels in the embryonic brain. The targeted disruption of M-x results in massive cell death of immature neurons in the developing mouse brain (Motoyama et al., 1995) . b&x-deficient mice die around embryonic day 13 (El 3), probably secondary to their inability to produce mature red blood cells. To determine whether the death of immature neurons in the b&x-deficient brain is cell autonomous, we examined primary telencephalic cell cultures from El 2.5 homozygous mutant @cl-x7'-), heterozygous mutant (k/-x"-), and wild-type (b&x+'+)
mice. b&x-'-telencephalic cells cultured in 0.5 or 2.0% fetal calf serum (FCS)-containing medium for 48 hr showed increased apoptosis, defined by abnormal bisbenzamide staining and terminal-deoxytransferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL), and decreased numbers of microtubule-associated protein-2Ammunoreactive neurons compared with b&x+'-and b&x+'+ cultures. Cycloheximide treatment of b&x-'-telencephalic cell cultures failed to prevent the increased cell death observed in low FCS-containing medium, suggesting a protein synthesis-independent apoptosis. There were no significant differences among b&x-'-, bcl-X +'-, and bcl-x+'+ telencephalic cells grown for 48 hr in 5% FCS-containing medium or in a chemically defined serum-free medium (ITS). bcl-x-'I neurons generated in ITS showed increased susceptibility to subsequent serum deprivation. These results indicate that bcl-x is important for both neuron maturation and survival.
Key words: apoptosis; programmed cell death; bcl-x; bcl-2; neuronal development; neuroprotection bcl-x is a member of the bcl-2 gene family, which is expressed at high levels in adult lymphoid tissues and the brain (Boise et al., 1993; Gonzilez-Garcia et al., 1994) . bcl-x can be alternatively spliced to produce two major protein isoforms, B&x, and Bcl-x,. B&x,, similar to 13~1-2, inhibits apoptosis, whereas Bcl-x, inhibits the antiapoptotic action of Bcl-2. In the mouse, bcl-x, is the predominant bcl-x mRNA and is widely expressed in embryonic tissues, where it appears to be more abundant than bcl-2 (Fang et al., 1994; Gonzglez-Garcia et al., 1994; Frankowski et al., 1995) . We have shown by in situ hybridization of embryonic day 12.5 (E12.5) mouse brain sections that bcl-x mRNA is low in rapidly proliferating ventricular zone cells and is highly expressed in cells in the more mature intermediate layer (Motoyama et al., 1995) . Immunohistochemical and in situ hybridization studies of Bcl-x distribution in mouse and human tissues indicate that it is expressed in neurons of both the central and peripheral nervous systems but not in glia (Krajewski et al., 1994; Frankowski et al., 1995) . The relatively high levels of Bcl-x, in the adult brain contrast with the low level of Bcl-2 staining in most mature adult CNS neurons (Merry et al., 1994) . Recent data indicate that, Recei ved Oct. 28, 1995; revised Dec. 1, 1995; accepted Dec. 3, 1995 similar to Bcl-2, Bcl-x, overexpression can block the in vitro nerve growth factor (NGF) deprivation-induced apoptotic death of sympathetic neurons (Martinou et al., 1994; Frankowski et al., 1995; Gonzilez-Garcia et al., 1995) . In total, these observations suggest that Bcl-x, may have an important neuroprotective role in the nervous system. To elucidate the functional and developmental role of Bcl-x, we used homologous recombination in embryonic stem (ES) cells to generate b&-deficient mice (Motoyama et al., 1995) . Heterozygous mutant mice (bcZ-xf'L) were healthy and normal in size. Homozygous mutant mice (hcl-x-/-) died around E13. Histological examination of El 1.5 and 12.5 b&x-'-, bcl-.x+'-, and wildtype (b&x+/+) mice revealed a striking abnormality in the bcl-X-'-nervous system. In the nervous system, there were large areas containing pyknotic nuclei, karyorrhectic debris, and phagocytic cells with engulfed debris. Mutant mice had a dramatic increase in terminal-deoxytransferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) in these sites, and large numbers of bright, condensed, or fragmented bisbenzamide-labeled nuclei were observed, suggesting apoptotic death.
The lymphoid system was also found to be severely affected in bcl-x-deficient mice. Because of early embryonic lethality, lymphocytic cell function was studied in bcl-x double-knockout chimeric mice. Similar to immature neurons, bcl-x deficiency resulted in the decreased survival of immature lymphocytes. Red blood cell maturation was also affected and probably accounts for the embryonic lethality of b&r-'-mice (N. Motoyama, K. Roth, S. Senju, and D. Lob, unpublished data). To determine whether neuronal apoptosis in bcl-x-deficient mice was cell-autonomous or secondary to the hematopoietic defect, and to begin to define the mechanisms of Bcl-x action, we examined primary cell cultures from the E12.5 telencephalon.
The El 2.5 telencephalon consists predominantly of immature neuroepithelial cells and shows only rare apoptotic cells in bcl-x-'-mice.
MATERIALS AND METHODS
Generation and detection of b&x-deficient mice. hcl-x-deficient mice were generated by homologous recombination in ES cells (Motoyama et al., 1995) . The endogenous and disrupted bcl-x genes were detected by PCR analysis of tail DNA extracts.
Prirnavy telencephalic cell cultures.
Primary cell cultures were prepared as described previously (Flaris et al., 1995) . Briefly, pregnant mice were killed on E12.5. The morning of the day that a vaginal plug was seen was designated as E0.5. The uterus was rapidly removed under sterile conditions, and the embryos were transferred to cold HBSS medium (Gibco, Grand Island, NY). The tails were harvested for DNA extraction and PCR analysis of genotype. The telencephalon was dissected away from the surrounding brain, and the pia and connective tissue were removed with forceps. The neuroepithelial cells were dissociated for 20 min in HBSS containing 0.01% trypsin, 0.004% EDTA, 0.04 mgiml DNase I, and 0.1% bovine serum albumin (BSA). Trypsinization was stopped with 1 vol of 10% fetal calf serum (FCS). Cells were dissociated further by two rounds of trituration with a fire-polished Pasteur pipette. Dissociated cells were washed twice with HBSS and 0.1% BSA, resuspended in HBSS, and counted on a hemocytometer. Cells were plated at -20,000 viable cells per 0.1 ml of medium in 48-well plates coated with poly+lysine and laminin. The serum-containing medium consisted of DMEMIF12 with 15 mM HEPES and I .2 gmil sodium bicarbonate, supplemented with 2 ITIM glutamine, 2.6 gm/l glucose, 0.66 pi/l 2-mercaptoethanol, and 0.5, 2.0, or 5.0% FCS (HyClone, Logan, UT). Chemically defined serum-free medium (ITS) was DMEM/F12 supplemented with 5 mgiml insulin, 100 mgiml transferrin, 100 PM putrescine, 30 nM selenium, and 20 mM progesterone. In some experiments, 30 PM 5'-bromo-2'-deoxyuridine (BrdU) was added to the culture medium immediately after plating. All reagents were purchased from Sigma (St. Louis, MO) unless indicated otherwise.
Immunohistochemical and TUNEL labeling. The immunohistochemical methods used in our laboratory have been described previously (Flaris et al., 1995; Motoyama et al., 1995) . Briefly, cell culture wells were fixed in 4% paraformaldehyde for 30 min at room temperature and subsequently incubated overnight at 4°C in diluted primary antiserum. After several wash steps, immunostaining was detected with fluorescently labeled secondary antibodies (Jackson Immunoresearch, West Grove, PA). An antibody against microtubule-associated protein-2 (MAP2; Sigma) was used to detect neurons in vitro. A goat anti-BrdU serum was used to detect cells that had incorporated BrdU in vitro (a gift from S. Cohn, Washington University). A modified TUNEL protocol was used to detect DNA fragmentation '(Gavrieli et al., 1992; Tornusciolo et al., 1996) . Briefly, cells were oermeabilized with 0.5% Triton X-100 in PBS and incubated with termi;al-deoxytransferaseand indocarbocyanine (Cy3)-conjugated deoxyuridine triphosphate. Cells were then processed for immunohistochemical labeling and bisbenzamide staining (0.1 mgiml for 30 min at room temperature).
The quantitation of immunoreactive and/or TUNEL-stained cells was performed by an investigator blind to the experimental conditions and the genotype of the cells being evaluated. In each experiment, cells from individual wells were quantitated from two to four representative 400X magnification microscopic fields. Statistical significance was determined by ANOVA, Student's t test, or x2 analysis.
RESULTS
Low FCS-containing medium increases apoptosis and decreases neuron generation in k/-x-deficient telencephalic cells
We compared the effect of FCS concentration (0.5,2.0, and 5.0%) on primary cultures of bcl-x-'p, bcl-x+fp, and bcl-x'-'+ E12.5 telencephalic cells. The number of cells, abnormal bisbenzamidelabeled nuclei, and MAPZ-immunoreactive neurons was quantitated at 2, 24, and 48 hr after plating. In 0.5 and 2.0% FCScontaining medium, bcl-x-deficient cultures were equivalent to wild-type and heterozygote cultures at 2 hr but showed fewer total cells, fewer neurons, and increased numbers of abnormal nuclei and bcl-x-'-E12.5 primary tclencephalic cell cultures. Primary cells were fixed after 2, 24, or 48 hr in culture, and the number of cells, apoptotic cells, and neurons were quantitated after immunolabeling for MAP2 and bisbenzamide staining. All data arc prcsented as a percentage of the viable cells present after 2 hr in culture. The number of viable cells (A, B) was determined by subtracting the number of abnormal bisbenzamide-stained nuclei from the total number of nuclei. Abnormal bisbenzamide-labeled nuclei were considered apoptotic (C, D), and MAP2 immunoreactivity was used as an indicator of neuronal differentiation (E, F). Data were obtained from 15 bci-x+'+, 15 bcl-x+'-, and 9
bcl-x-'-individual telencephalic cell cultures, and the total number of cells counted at 2 hr in culture for each group was 1936,2075, and 1274 in 2.0% FCS-containing medium and 2172, 2112, and 1194 in 0.5% FCScontaining medium, respectively (*I, < 0.01 vs bcl-x".' ).
at 24 and 48 hr (Fig. 1) . bcl-x+'-telencephalic cell cultures were similar to bcl-x+'+ cultures at all concentrations of FCScontaining medium tested.
Bisbenzamide staining of condensed, clumped, and/or fragmented nuclei has been used as an indicator of apoptotic death in vitro (Deckwerth and Johnson, 1993) . To verify that abnormal bisbenzamide-stained nuclei actually represented apoptotic cells, we performed simultaneous TUNEL labeling and bisbenzamide staining on E12.5 bcl-x-'-telencephalic cell cultures after 48 hr in either 0.5 or 2.0% FCS-containing medium. Both TUNEL labeling and abnormal bisbenzamide staining revealed an approximately threefold increase in the number of apoptotic cells in 0.5 versus 2.0% FCS-containing medium (TUNEL-labeled nuclei: 39 +-10 at 0.5% FCS, 14 ? 2 at 2.0% FCS; abnormal bisbenzamidestained nuclei: 33 5 10 at 0.5% FCS, 9 ? 3 at 2.0% FCS) (n = 3). Dual labeling also showed concordance of the two methods for detecting apoptotic cells (Fig. 2&I) .
In contrast to the effect of low FCS concentrations on bcl-xp'p cells, there were no statistical differences among bcl-x-deficient, heterozygote, and wild-type cultures grown in 5.0% FCScontaining medium. After 2 hr in culture medium, -17% of the telencephalic cells were in S-phase of the cell cycle as determined by in vitro BrdU labcling @cl-x+'+: 141 BrdU-positive nuclei of 850 total nuclei counted, II = 7; hcl-x+'-: 1391904, n = 7; bcl-x-l-: 681366,n = 3). By 24 hr, cumulative BrdU labeling revealed that -60% of the cells had entered S-phase in vitro (bcl-x+'+: 1316/ 2116, n = 9; bcl-x+'-: 144412458, n = 12; bcl-x-l-:
68811098, II = 6), and by 48 hr -75% of the cells were BrdU-labeled @cl-x+'+: 191812462, n -9; bcl-x+'-: 240413356, n = 12; bcl-x-l-: 83311157, IZ = 6). The percentage of cells with MAP2 immunoreactivity was similar among the three groups at 2, 24, and 48 hr in vitro. Approximately 13% of the cells in culture possessed MAP2 immunoreactivity at 2 hr (bcl-x+'+: 2.58 MAP2 immunoreactive cells of 1916 total cells examined, n = 14; bcl-x+'-: 30812114, y1 = 15; bcl-x-l-: 151/1230, n = 9), and this increased to -25% of the cells at 24 and 48 hr (data not shown). Initially, ~1% of the MAPZ immunoreactive cells contained cell processes, but this increased rapidly to -15, 40, and >90% at 6, 12, and 24 hr, respectively (data not shown). Cumulative BrdU labeling indicated that -10% of the MAP2-immunoreactive cells observed at 48 hr had been in S-phase during the culture period (data not shown). The percentage of abnormal bisbenzamide-labeled nuclei at 2, 6, 12, 24, and 48 hr did not differ significantly among the groups. For example, at 24 hr, <l% of the cell nuclei in each group (2213102 wild-type cell nuclei, n = 15; 7/2906 heterozygote nuclei, n = 15; 7/1532 homozygous nuclei, n = 9) were considered abnormal. In total, these results indicate that in vitro telencephalic cell proliferation, differentiation, and death are equivalent in b&x-deficient, heterozygote, and wild-type cultures grown in 5.0% FCS-containing medium.
Cycloheximide does not block the increased apoptosis of b&x-deficient telencephalic cells in low FCScontaining medium Because bcl-x-'-telencephalic cells showed increased apoptosis in 2.0% FCS-containing medium compared with wild-type and heterozygote cells, we tested the ability of cycloheximide, a protein synthesis inhibitor, to block the increased cell death. Qcloheximide, at 1 or 5 &ml, was added to the cultures at 0, 18, or 24 hr after plating. These doses were chosen based on their previously reported ability to block protein synthesis and to prevent apoptosis of NGF-deprived sympathetic neurons (Deckwerth and Johnson, 1993). Forty-eight hours after plating, the num- Cycloheximide &g/ml) F&ure 3. Effect of cycloheximide on E12.5 bcl-x*'+, bcl-x+'-, and bclx? primary cell cultures. Cells were plated at time 0 in 2.0% FCScontaining medium, and cycloheximide (0, 1, or 5 Fg/ml) was added 24 hr later. After an additional 24 hr, the cells were fixed and the number of apoptotic cells (A) was determined by abnormal bisbenzamide staining, and the number of neurons (B) by MAP2 immunoreactivity. The data represent the mean i SEM; n = 5, 4, and 3 for bcl-x+'+, bcl-x+'-, and bcl-xm'm cells, respectively. *p < 0.05 versus zero cycloheximide treatment, ber of cells, MAP2-immunoreactive neurons, and abnormal bisbenzamide-stained nuclei was assessed. Cycloheximide at both doses and at all incubation times tested decreased the total number of cells and MAP2-immunoreactive neurons at 48 hr in bcl-x-l-, bcl-x+lp, and bcl-x+l+ telencephalic cell cultures (Fig. 3 and data not shown). Cycloheximide had no significant effect on the number of abnormal bisbenzamide-stained nuclei in control or heterozygote cell cultures. In bcl-x-deficient cell cultures, which at baseline had an approximately threefold increase in abnormal nuclei over wild-type cultures, cycloheximide addition exacerbated the effect of bcl-x deficiency (Fig. 3 and data not shown) .
b&x-'-, b&x+'-, and b&x+'+ telencephalic cells are similar in a chemically defined serum-free medium b&x-deficient telencephalic cells were equivalent to wild-type cells in 5.0% FCS-containing medium. Because 5% FCScontaining medium promotes cell proliferation, and only -25% of the cells in culture at 48 hr possess MAP2 immunoreactivity, we compared bcl-x-l-, bcl-x+'-, and bcl-x+'+ primary telencephalic cells grown in ITS. bcl-xp'p, bcl-xt'p, and bcl-x+'+ telencephalic cells appeared similar after 48 hr in ITS medium. Total cell numbers showed no significant increase between 2 and 48 hr in culture, and MAP2-immunoreactive cells represented ~50% of the total cells at 48 hr (data not shown). The number of abnormal bisbenzamide-stained nuclei observed at 48 hr was increased in all groups over 5. bcl-x-l-, a = 3). *p < 0.05 versus bcl-x+'m. n = 8) and in TUNEL-positive cells (bcl-x+'+: 12%, 27 TUNELpositive nuclei in 232 cells, n = 2; bcl-x+'-: 16%, 177/1093, n = 8; bcl-x-l-:
18%, 96/533, n = 4). Culturing of El25 telencephalic cells in ITS medium for an additional 48 or 96 hr resulted in a progressive increase in abnormal bisbenzamide-labeled nuclei and, ultimately, a decline in the number of MAP2-immunoreactive neurons in all groups (data not shown).
Serum deprivation of b&x-deficient neurons leads to rapid neuronal apoptosis bcl-x-l-, bcl-x'l-, and bcl-x'l' E12.5 telencephalic cell cultures were roughly equivalent after 48 hr in ITS. To determine whether bcl-x deficiency increased the vulnerability of neurons that had matured for 48 hr in ITS, we switched the cells to low FCS (0.5, 1.0, or 2.0%)-containing medium and quantitated the number of cells, abnormal bisbenzamide-stained nuclei, and MAPZ immunoreactive neurons 24-96 hr later. For wild-type cells, there was no significant change in the number of neurons or apoptotic cells when the cells were switched to 2.0% FCS for up to 96 hr (data not shown). Switching cells to 0.5% FCS resulted in a significant loss of neurons and increased apoptosis at 96 hr but not 48 hr after switch (data not shown). Examination of bcl-xtlp telencephalic cells revealed an FCS dose dependence and time course similar to bcl-x+'+ cells (Fig. 4) . In contrast, bcl-x-deficient cells exhibited a greater serum sensitivity and a more rapid time course of neuron loss and apoptosis than bcl-xt'p cells (Fig. 4) . We performed TUNEL labeling on bcl-x+'p and bcl-xp'p telencephalic cells to verify that the abnormal bisbenzamide-stained cells were apoptotic (Fig. 2C,D) . Twenty-four hours after the switch to 0.5% FCS-containing medium, there were almost twice as many TUNEL-positive nuclei in bcl-x-'-cultures than in bcl-xtip cultures, and by 72 hr the difference was threefold (Fig.  4) . Similar but less dramatic changes were observed in 2.0% FCS-containing medium.
DISCUSSION
Our studies indicate that bcl-x-deficient telencephalic cells are highly susceptible to apoptotic death in vitro. These findings suggest several interesting conclusions. First, the apoptotic death of neurons in the embryonic bcl-xp'p nervous system is probably not attributable to hematopoietic dysfunction because it can be recapitulated in primary neuronal cell cultures. Immunohistochemical studies indicate that Bcl-x is not expressed in glia; therefore, the apoptosis of bcl-x-deficient neurons is probably a cell autonomous process. Second, the death of immature bcl-xdeficient neurons can be prevented in vitro by 5.0% FCS or by ITS. This indicates that bcl-x-independent antiapoptotic pathways exist in immature neurons, and that these pathways can overcome the deleterious effect of bcl-x deficiency. Although extensive apoptosis of immature neurons is seen in the El25 bcl-x-'-nervous system, mature neurons are also present. It is unclear whether these neurons survive in vivo because they are truly bcl-x-independent or whether there are sufficient survival factors present in the developing nervous system to activate bcl-x-independent, antiapoptotic pathways and to rescue a subpopulation of immature neurons from bcl-x deficiency. An examination of the nervous system of double-knockout chimeric mice would permit an assessment of bcl-x-dependent and -independent neuronal subpopulations. Third, the inability of cycloheximide to block cell death suggests that new protein synthesis is not required for triggering apoptosis in bcl-x-deficient immature neurons. Protein-and RNA synthesisindependent neuronal apoptosis has been described in the nervous system (Galli et al., 1995) . Because cycloheximide actually increased cell death in bcl-x-deficient neuronal cultures but not in heterozygote or wild-type cultures, this suggests that the survival of bcl-x-deficient cells requires ongoing protein synthesis and, thus, may be actively regulated. Fourth, bcl-x-deficient neurons that had differentiated in vitro were more susceptible to serum deprivation than bcl-x-t'p and bcl-x+'+ neurons, suggesting that bcl-x may play a significant neuroprotective role in mature neurons. In contrast to bcl-2, bcl-x is highly expressed in neurons throughout the adult CNS (Frankowski et al., 199.5) suggesting an important role for bcl-x in regulating mature neuron survival. In the adult nervous system, neuronal apoptosis occurs in several pathophysiological states (Dickson, 1995) . Recent data suggest that a significant portion of the neurons that are lost after a stroke (hypoxic/ischemic insult) dies via apoptosis (Linnik et al., 1993; Nitatori, 1995) . Bcl-x, can prevent hypoxia-induced cell death in PC12 cell lines, although the mechanisms of its antiapoptotic action are unclear (Shimizu et al., 1995) . Neurodegenerative diseases, including Alzheimer's and Huntington's diseases, may also produce the apoptotic death of neurons (Lassmann et al., 1995; Portera-Cailliau et al., 1995) . Because bcl-x expression appears to be important for the survival of mature neurons and because several neuropathological processes cause neuron death via apoptotic pathways, bcl-x may play a significant role in protecting neurons in the adult brain from neurodegenerative diseases and hypoxic/ischemic insults.
Our in vivo and in vitro results indicate that Bcl-x is a critical regulator of neuronal apoptosis during nervous system development. Apoptotic neuronal death occurs under a variety of circumstances in the developing nervous system (Oppenheim, 1991; Pittman, 1994; Raff et al., 1995) . These include after terminal mitotic division but before the formation of synaptic contacts, during the competition for target-derived trophic factors, after synaptic contacts have been made, and after the loss of presynaptic inputs. Neuron death before synapse formation and before neurotrophic factor dependence has received relatively scant attention; however, it has been described in the retina, spinal cord, sensory ganglia, and telencephalon (Maruyama and D'Agostino, 1967; Lance-Jones, 1982; Oppenheim, 1991; Acklin and van der Kooy, 1993; Homma et al., 1994) . The extent of cell death during this presynaptogenic period is difficult to determine precisely, in large part because of the rapidity with which dead cells are phagocytized (Ferrer et al., 1991 (Ferrer et al., , 1992 ). An interesting analysis performed by Acklin and van der Kooy (1993) on the late embryonic rat brain suggests that extensive presynaptogenic cell death occurs in telencephalic precursor cell lineages. Individual precursor cells in the E17-El9 rat telencephalon were labeled with a retroviral "tag," and the fates of their daughter cells were analyzed by [3H]thymidine labeling. They found that -80% of the precursors analyzed gave rise to at least one daughter cell that died within 48 hr of initial labeling. This report confirmed earlier observations of degenerative profiles in the immature mouse embryonic telencephalon (Smart and McSherry, 1982) . Acklin and van der Kooy (1993) could not determine the phenotype of the dying cells but, based on the known developmental sequence of neurogenesis and gliogenesis in the rodent telencephalon (Angevine et al., 1970; Takahashi et al., 1992 Takahashi et al., , 1995 , it is likely that the dead cells represent neuronal progenitors and/or early postmitotic neurons. These authors suggested that this form of cell death might regulate the numbers and types of cells generated in any given cortical region, perhaps via local factors secreted by more mature cells.
In total, our work and these previous observations on immature neuronal death suggest that regulated expression of bcl-x may underlie early selection events in the developing nervous system. The cellular and molecular signals that regulate bcl-x expression in immature neurons require additional investigation. 
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